Joe Bradley
Little Rock, ARNPI 1700888799
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 58.7% of the total. Reporting peaked in 2019 at $9,021 and has fallen 86.0% since, to $1,263 in 2025.
Across 414 payments — averaging $36.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Axsome Therapeutics, Inc.$787
- Teva Pharmaceuticals USA, Inc.$723
- Lundbeck LLC$717
- AbbVie$683
- Otsuka America Pharmaceutical, Inc.$570
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$7,20048%
- Travel & lodging$8886%
- Food & beverage$6,74945%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $8,753 |
| Axsome Therapeutics, Inc. | 39 | $787 |
| Teva Pharmaceuticals USA, Inc. | 45 | $723 |
| Lundbeck LLC | 36 | $717 |
| AbbVie(2 entities) | 50 | $683 |
| Otsuka America Pharmaceutical, Inc. | 33 | $570 |
| Supernus Pharmaceuticals, Inc. | 22 | $340 |
| Almatica Pharma LLC | 13 | $253 |
| Neurocrine Biosciences, Inc. | 13 | $241 |
| Avanir Pharmaceuticals, Inc. | 14 | $237 |
| Alkermes, Inc. | 13 | $232 |
| Vanda Pharmaceuticals Inc. | 22 | $217 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $208 |
| Johnson & Johnson(2 entities) | 11 | $192 |
| Tris Pharma Inc | 7 | $129 |
| Corium, LLC | 7 | $108 |
| Noven Therapeutics, LLC | 5 | $96 |
| Bausch Health US, LLC | 5 | $78 |
| Idorsia Pharmaceuticals US Inc | 5 | $74 |
| Merck | 4 | $63 |
| Shire North American Group Inc | 4 | $55 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$8,070
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $214,569 |
| AustedoDeutetrabenazine | 12 | $132,252 |
| TrintellixVortioxetine Hydrobromide | 163 | $87,431 |
| RexultiBrexpiprazole | 34 | $48,460 |
| Lurasidone Hcl | 99 | $23,486 |
| VraylarCariprazine Hcl | 13 | $20,818 |
| CaplytaLumateperone Tosylate | 13 | $20,652 |
| BelsomraSuvorexant | 42 | $18,058 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 302 | $10,055 |
| Lisdexamfetamine Dimesylate | 38 | $9,779 |
| Doxepin Hcl | 56 | $7,483 |
| DayvigoLemborexant | 22 | $7,055 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 77 | $6,805 |
| Alprazolam | 920 | $6,740 |
| ConcertaMethylphenidate Hcl | 13 | $5,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $241 | $214,56925 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $723 | $132,25212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $8,753 | $87,431163 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $570 | $48,46034 claims |
| AbbVieVraylar | $683 | $20,81813 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $208 | $20,65213 claims |
| MerckBelsomra | $63 | $18,05842 claims |
| Eisai Inc.Dayvigo | $11 | $7,05522 claims |
| Johnson & JohnsonConcerta | $192 | $5,95613 claims |
| Almatica Pharma LLCSertraline Hcl | $253 | $1,147103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Arkansason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.